Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

Moderna (NASDAQ:MRNA – Free Report) had its price objective decreased by Evercore ISI from $60.00 to $50.00 in a research ...

Moderna's trailing-12-month revenue ... Part of the issue is that its RSV vaccine only brought in $10 million in the third quarter, due to its late approval relative to the peak infection season ...

The expansion of Heathrow Airport and the building of the Lower Thames Crossing are among the schemes backed as part of ...

Andy predicts the rise in trends such as predictive analytics to predict waves such as the next pandemic or even individual health related diseases or illnesses.

So, he went ahead and added the theme song. The ABC host immediately zeroed in on the hearing during his Wednesday monologue, calling out RFK Jr. for having "conveniently evolved" on issues like ...

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt.

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in Phase 3 clinical trials, with the potential to be the first approved ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...